FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Moderna, Inc. Granted Provisional Registration for its Covid-19 Vaccine by the Therapeutic Goods Administration”
Moderna, Inc. (NASDAQ: MRNA) climbed over 11% over its previous close by midday trading after the company announced that the Therapeutic Goods Administration had granted a provisional registration for the company’s COVID-19 Vaccine.
Delivery of Moderna’s COVID-19 vaccine to Australia is expected to commence in the second half of September with the Australian government having previously secured 10 million doses of COVID-19 Vaccine Moderna for delivery in 2021, as well as an option to procure 15 million doses in 2022.
Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing.
For more information, please visit: Moderna, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.